Skip to main content
. Author manuscript; available in PMC: 2017 Jun 8.
Published in final edited form as: Asian Pac J Cancer Prev. 2012;13(5):2369–2378. doi: 10.7314/apjcp.2012.13.5.2369

Table 5.

Reasons for and against HPV vaccination

General Female Population
Healthcare Providers
Government Officials
Urban Rural Urban Rural Urban Rural
Reasons for willingness to be vaccinated, multiple answers allowed (number, %)
N=3,661 N=5,358 N=284 N=338 N=280 N=372
Self-benefit 2,678 (73.1) 4,165 (77.7) 235 (82.7) 273 (80.8) 213 (76.1) 283 (76.1)
Benefit to other youth 542 (14.8) 912 (17.0) 24 (8.5) 67 (19.8) 55 (19.6) 100 (26.9)
Fear of cervical cancer 1,992 (54.4) 3,503 (65.4) 171 (60.2) 228 (67.5) 163 (58.2) 247 (66.4)
Fear of genital warts 483 (13.2) 944 (17.6) 69 (24.3) 111 (32.8) 48 (17.1) 93 (25.0)
Fear of HPV infection 1,383 (37.8) 1,590 (29.7) 142 (50.0) 173 (51.2) 120 (42.9) 163 (43.8)
Fear of having been infected with HPV 272 (7.4) 290 (5.4) 31 (10.9) 59 (17.5) 33 (11.8) 35 (9.4)

Reasons against willingness to be vaccinated, multiple answers allowed (number, %)
N=1,100 N=1,561 N=70 N=68 N=72 N=39
Belief in low self-risk 302 (27.5) 598 (38.3) 23 (32.9) 14 (20.6) 17 (23.6) 14 (35.9)
Limited usage to date 434 (39.5) 353 (22.6) 31 (44.3) 32 (47.1) 21 (29.2) 14 (35.9)
Belief that vaccination is risky 563 (51.2) 489 (31.3) 49 (70.0) 42 (61.8) 52 (72.2) 26 (66.7)
Doubt of vaccine efficacy 365 (33.2) 326 (20.9) 39 (55.7) 37 (54.4) 32 (44.4) 17 (43.6)
Doubt of source of vaccine 164 (14.9) 160 (10.2) 12 (17.1) 10 (14.7) 14 (19.4) 3 (7.7)
Expense of vaccine 226 (20.5) 579 (37.1) 9 (12.9) 14 (20.6) 9 (12.5) 8 (20.5)
Other 87 (7.9) 144 (9.2) 2 ( 2.9) 2 (2.9) 0 (0.0) 0 (0.0)